AstraZeneca Plc and Bristol Myers Squibb held preliminary discussions regarding a potential merger, which, if materialized, would establish one of the world's largest pharmaceutical companies with an estimated combined value of nearly $400 billion. The Financial Times was the first to report this development, though it remains unclear if these talks are ongoing. This potential megadeal could significantly reshape the global pharmaceutical landscape.
The proposed acquisition carries considerable regulatory risks, particularly concerning how it might be scrutinized by U.S. antitrust authorities under President Donald Trump's administration. Trump's focus on promoting domestic investments and expanding U.S. manufacturing could complicate approval, especially as AstraZeneca, a UK-based company, would effectively be acquiring a major U.S. pharmaceutical player. Analysts, such as Andre Barlow of DBM Law Group, anticipate that a Trump-era Federal Trade Commission (FTC) would meticulously examine the merger for overlaps in drugs and late-stage pipelines, potentially requiring significant divestitures, similar to the FTC's demand for Celgene to sell its psoriasis treatment Otezla during its acquisition by Bristol Myers in 2019.
Both companies exhibit strong growth in their oncology portfolios, a factor that could draw antitrust attention. Cancer treatments constituted approximately $25 billion of AstraZeneca's 2025 sales, making up nearly half of its total revenue, while oncology drugs accounted for over 40% of Bristol Myers' overall sales in the first six months of 2026. Their cancer immunotherapies directly compete, suggesting that such overlaps could lead to divestiture requirements. Bristol Myers is actively pursuing smaller deals to acquire new drugs as some of its older medicines, including its former top seller Revlimid, are losing patent protection, and current top sellers like Opdivo and Eliquis face patent expiration by 2028. AstraZeneca's share price has quadrupled under CEO Pascal Soriot's 14-year leadership, driven by strong demand for its cancer and rare-disease drugs.
